CoChat
Sign Up
Cited by 805

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The role of COX‐2 in intestinal inflammation and colorectal cancer

Wang, D, DuBois, R N·2010·Oncogene
DOI 10.1038/onc.2009.421PMC PMC3181054
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2009.421

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 100

  1. Al-Salihi MA, Terrece Pearman A, Doan T, Reichert EC, Rosenberg DW, Prescott SM et al. (2009). Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett 273: 225–232. · DOI
  2. Anderson GD, Keys KL, De Ciechi PA, Masferrer JL . (2009). Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res 58: 109–117. · DOI
  3. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885–895. · DOI
  4. Aruajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A et al. (2009). Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 27: 391–396. · DOI
  5. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES et al. (2005). 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217–3223. · DOI
  6. Barry M, Cahill RA, Roche-Nagle G, Neilan TG, Treumann A, Harmey JH et al. (2009). Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Ir J Med Sci 178: 201–208. · DOI
  7. Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH . (2002). Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 8: 356–361. · DOI
  8. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2: 310–321. · DOI
  9. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873–884. · DOI
  10. Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN . (2007). Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67: 9380–9388. · DOI
  11. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS . (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504–1510. · DOI
  12. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS . (2008). Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134: 21–28. · DOI
  13. Chan AT, Ogino S, Fuchs CS . (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131–2142. · DOI
  14. Chan AT, Ogino S, Fuchs CS . (2009). Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649–658. · DOI
  15. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C et al. (2000). Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705–4708.
  16. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T et al. (2008). Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10: 782–796. · DOI
  17. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP et al. (2008). Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68: 5619–5627. · DOI
  18. Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM et al. (2004). Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64: 279–285. · DOI
  19. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB et al. (1998). Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073. · DOI
  20. Dudhgaonkar SP, Tandan SK, Kumar D, Raviprakash V, Kataria M . (2007). Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 15: 188–195. · DOI
  21. Eaden J . (2003). Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2): 15–21. · DOI
  22. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN . (1994). Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188. · DOI
  23. El Miedany Y, Youssef S, Ahmed I, El Gaafary M . (2006). The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101: 311–317. · DOI
  24. Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P et al. (2008). Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 62: 717–725. · DOI
  25. Falandry C, Canney PA, Freyer G, Dirix LY . (2009). Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 20: 615–620. · DOI
  26. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G . (2000). Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95: 1949–1954. · DOI
  27. Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P et al. (2006). Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 57: 185–190. · DOI
  28. Flossmann E, Rothwell PM . (2007). Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603–1613. · DOI · Paper page
  29. Forman BM, Chen J, Evans RM . (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312–4317. · DOI · Paper page
  30. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM . (1995). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803–812. · DOI
  31. Gould SR, Brash AR, Conolly ME, Lennard-Jones JE . (1981). Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med 6: 165–182. · DOI
  32. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481. · DOI
  33. Grover JK, Yadav S, Vats V, Joshi YK . (2003). Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 18: 279–291. · DOI
  34. Gupta RA, DuBois RN . (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11–21. · DOI
  35. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK et al. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97: 13275–13280. · DOI
  36. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J . (2002). Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403–408.
  37. Harrington LE, Mangan PR, Weaver CT . (2006). Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18: 349–356. · DOI
  38. Harris RE . (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55–67. · DOI
  39. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C et al. (2007). Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer 7: 221. · DOI
  40. Izzo AA, Camilleri M . (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57: 1140–1155. · DOI
  41. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B et al. (1994). Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54: 5523–5526.
  42. Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L . (2007). The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 320: 22–28. · DOI
  43. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E et al. (2002). The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109: 883–893. · DOI
  44. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K . (2003). Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985–990. · DOI
  45. Kelloff G, Fay J, Steele V, Lubet R, Boone C, Crowell J et al. (1996). Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5: 657–666.
  46. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM . (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813–819. · DOI · Paper page
  47. Kohno H, Suzuki R, Sugie S, Tanaka T . (2005). Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5: 46. · DOI
  48. Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW et al. (2008). Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 29: 1648–1654. · DOI
  49. Lewis JD, Deren JJ, Lichtenstein GR . (1999). Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am 28: 459–477, x. · DOI
  50. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563–18569. · DOI
  51. MacDermott RP . (1994). Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 78: 1207–1231. · DOI
  52. Mahadevan U, Loftus Jr EV, Tremaine WJ, Sandborn WJ . (2002). Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97: 910–914. · DOI
  53. Marnett LJ, DuBois RN . (2002). COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42: 55–80. · DOI
  54. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P et al. (2004). Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101: 133–138. · DOI
  55. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM . (2004). Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 279: 43261–43272. · DOI
  56. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O et al. (2000). Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105: 469–478. · DOI
  57. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G . (2002). Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99: 12483–12488. · DOI
  58. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T et al. (2002). Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62: 28–32.
  59. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A et al. (2006). 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103: 12098–12102. · DOI
  60. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP et al. (2008). Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68: 3251–3259. · DOI
  61. Narasimha A, Watanabe J, Lin JA, Hama S, Langenbach R, Navab M et al. (2007). A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat 84: 24–33. · DOI
  62. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K et al. (2008). Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14: 8221–8227. · DOI
  63. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803–809. · DOI
  64. Patsos HA, Hicks DJ, Dobson RR, Greenhough A, Woodman N, Lane JD et al. (2005). The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54: 1741–1750. · DOI
  65. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN et al. (1992). APC mutations occur early during colorectal tumorigenesis. Nature 359: 235–237. · DOI
  66. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C et al. (2006). A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12: 3381–3388. · DOI
  67. Rigas B, Goldman IS, Levine L . (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518–523.
  68. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ et al. (2002). Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99: 1521–1526. · DOI
  69. Rockwell CE, Raman P, Kaplan BL, Kaminski NE . (2008). A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem Pharmacol 76: 353–361. · DOI
  70. Rodriguez DA, Tapia JC, Fernandez JG, Torres VA, Munoz N, Galleguillos D et al. (2009). Caveolin-1-mediated suppression of cyclooxygenase-2 via a /{beta/}-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin. Mol Biol Cell 20: 2297–2310. · DOI
  71. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C et al. (2007). Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 376–389. · DOI
  72. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883–890. · DOI
  73. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN . (2000). Cyclooxygenase-2 expression is increased in the subepithelial myofibroblasts of colon and cecal carcinomas from IL-10 (−/−) mice. Gastroenterology 118: 337–345. · DOI
  74. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R et al. (2007). The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis. J Immunol 178: 8138–8147. · DOI
  75. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF . (1998). Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297–306. · DOI
  76. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV et al. (1994). Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 54: 5527–5530.
  77. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B et al. (2006). Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114: 1028–1035. · DOI
  78. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM et al. (2008). Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104–2113. · DOI
  79. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S et al. (2001). Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048–1051. · DOI
  80. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952. · DOI
  81. Steinman L . (2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139–145. · DOI
  82. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G et al. (2009). MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315: 1439–1447. · DOI
  83. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K . (2008). Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28: 629–638.
  84. Van Dross RT . (2009). Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog 48: 724–732. · DOI
  85. Vane JR . (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232–235.
  86. Vane JR, Bakhle YS, Botting RM . (1998). Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120. · DOI
  87. Wang D, Dubois RN . (2006). Prostaglandins and cancer. Gut 55: 115–122. · DOI
  88. Wang D, Dubois RN . (2008). Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res 2008: 931074. · DOI
  89. Wang D, Mann JR, DuBois RN . (2005). The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128: 1445–1461. · DOI
  90. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al. (2006a). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941–951. · DOI
  91. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W et al. (2006b). Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 103: 19069–19074. · DOI
  92. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B et al. (2004). Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285–295. · DOI
  93. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H et al. (1999). Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093–5096.
  94. Wolfe MM, Lichtenstein DR, Singh G . (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899. · DOI
  95. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P et al. (2009). 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 106: 9409–9413. · DOI
  96. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP et al. (2005). Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950–3957. · DOI
  97. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA . (2009). The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136: 1669–1679. · DOI
  98. Zhang J, Chen C . (2008). Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 283: 22601–22611. · DOI
  99. Zhao S, Cai J, Bian H, Gui L, Zhao F . (2009). Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest 27: 636–640. · DOI
  100. Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM et al. (2009). Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst 101: 762–767. · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, D., & DuBois, R. N.
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2009-11-30
Volume
29
Issue
6
Pages
781-788
ISSN
  • 0950-9232
  • 1476-5594
DOI
10.1038/onc.2009.421
PMC
PMC3181054
Cited by
805
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review